Celecoxib-d₇

Celecoxib-d₇ is intended for use as an internal standard for the quantification of celecoxib (Item No. 10008672) by GC- or LC-MS. Celecoxib is a selective inhibitor of COX-2 (IC₅₀s = 22.9 and 0.05 μM for COX-1 and COX-2, respectively).^1,2 It displays chemopreventive activity in multiple tumor types via proapoptotic effects that are independent of COX-2 inhibition.^3,4,5 Formulations containing celecoxib have been used in the treatment of inflammation while circumventing the gastrointestinal toxicity associated with traditional non-sterodial anti-inflammatory drugs, however, the use of celecoxib has been tempered due to its ability to induce adverse cardiovascular events.⁶

WARNING This product is not for human or veterinary use.

1. Uddin, M.J., Rao, P.N.P., and Knaus, E.E. Design and synthesis of novel celecoxib analogues as selective cyclooxygenase-2 (COX-2) inhibitors: Replacement of the sulfonamide pharmacophore by a sulfonylazide bioisostere. Bioorg. Med. Chem. 11(23), 5273-5280 (2003).

2. Mardini, I.A., and Fitzgerald, G.A. Selective inhibitors of cyclooxygenase-2: A growing class of anti-inflammatory drugs. Mol. Interv. 1(1), 30-38 (2001).

3. Jendrossek, V., Handrick, R., and Belka, C. Celecoxib activates a novel mitochondrial apoptosis signaling pathway. The FASEB Journal 17(11), 1547-1549 (2003).

4. Leahy, K.M., Ornberg, R.L., Wang, Y., et al. Cyclooxygenase-2 inhibition by celecoxib reduces proliferation and induces apoptosis in angiogenic endothelial cells in vivo. Cancer Res. 62, 625-631 (2002).

5. Zhu, J., Huang, J.W., Tseng, P.H., et al. From the cyclooxygenase-2 inhibitor celecoxib to a novel class of 3-phosphoinositide-dependent protein kinase-1 inhibitors. Cancer Res. 64, 4309-4318 (2004).

6. Blobaum, A.L., and Marnett, L.J. Structural and functional basis of cyclooxygenase inhibition. J. Med. Chem. 50(7), 1425-1441 (2007).